SCHEMBL606801

SCHEMBL606801

O=C(CN1C(=O)CN(CCCNC2=NCCN2)C1=O)NC[C@H](NC(=O)C(=O)c1ccccc1)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ITGAV P06756 20/20 0.52
ITGB3 P05106 18/20 0.52
ITGA2B P08514 4/20 0.38
ITGB1 P05556 2/20 0.36
ITGB5 P18084 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5066046 1.00 ITGAV (0.52) ITGAVITGB3ITGA2BITGB1ITGB5
SCHEMBL7212659 0.90 ITGAV (0.56) ITGAVITGB3ITGA2BITGB1
SCHEMBL7217721 0.87 ITGB3 (0.70) ITGAVITGB3ITGA2B
SCHEMBL7211708 0.81 ITGB3 (0.76) ITGAVITGB3ITGA2B
SCHEMBL7216496 0.75 ITGB3 (0.68) ITGAVITGB3ITGA2B
SCHEMBL7211353 0.73 ITGB3 (0.66) ITGAVITGB3ITGA2B
SCHEMBL7212726 0.70 ITGB3 (0.53) ITGAVITGB3ITGA2B
SCHEMBL7212708 0.69 ITGB3 (0.58) ITGAVITGB3ITGA2B
SCHEMBL7974391 0.69 ITGB3 (0.52) ITGAVITGB3ITGA2B
SCHEMBL244300 0.69 ITGB3 (1.00) ITGAVITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-9255664-A None JP disclosed
US-9326934-B2 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG 2016-05-03 US disclosed
EP-2181704-B1 Drug delivery from rapid gelling polymer composition ANGIOTECH INT AG (CH) 2015-05-06 EP disclosed
US-8486437-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-07-16 US disclosed
US-8481073-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-07-09 US disclosed
US-8460708-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-06-11 US disclosed
US-20130012683-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-01-10 US disclosed
US-8303973-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2012-11-06 US disclosed
US-20120252905-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG 2012-10-04 US disclosed
EP-1708694-B1 COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE ANGIOTECH INT AG (CH) 2012-07-11 EP disclosed
US-20050152945-A1 Soft tissue implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-14 US disclosed
US-20050149157-A1 Electrical devices and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-07 US disclosed
US-20050149080-A1 Medical implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-07 US disclosed
US-20050149158-A1 Medical implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-07 US disclosed
US-20050143817-A1 Medical implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-06-30 US disclosed
US-20050142162-A1 Soft tissue implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-06-30 US disclosed
US-20040260318-A1 Anastomotic connector devices ANGIOTECH INTERNATIONAL AG (CH) 2004-12-23 US disclosed
US-20040225077-A1 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG (CH) 2004-11-11 US disclosed
US-20010021708-A1 Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors WEHNER VOLKMAR (DE) 2001-09-13 US disclosed
JP-H09255664-A NEW BONE-RESORPTION INHIBITOR AND ANTAGONIST FOR VITRONECTIN RECEPTOR HOECHST AG 1997-09-30 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050142162-A1 Soft tissue implants and anti-scarring agents MMP1, COL2A1, FN1 ITGAV 1232/4885ITGB3 625/4885ITGA2B 928/4885
US-20120252905-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION PGF, VCAM1, COL14A1 ITGAV 38/4885ITGB3 29/4885ITGA2B 20/4885
US-20010021708-A1 Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors ADGRF1, CALCR, SOST ITGAV 478/4885ITGB3 500/4885ITGA2B 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.